Literature DB >> 20829618

Cardiovascular disease in Cushing's syndrome: heart versus vasculature.

Monica De Leo1, Rosario Pivonello, Renata S Auriemma, Alessia Cozzolino, Pasquale Vitale, Chiara Simeoli, Maria Cristina De Martino, Gaetano Lombardi, Annamaria Colao.   

Abstract

Cushing's syndrome (CS) causes metabolic abnormalities that determine an increased cardiovascular risk not only during the active phase of the disease but also for a long time after cure. Cardiovascular complications, such as premature atherosclerosis, coronary artery disease, heart failure, and stroke, in patients with CS cause a mortality rate higher than that observed in a normal population. The increased cardiovascular risk is mainly due to metabolic complications, such as metabolic syndrome, but also to vascular and cardiac alterations such as atherosclerosis and cardiac structural and functional changes. In the clinical management of patients with CS the focus should be on identifying the global cardiovascular risk and the aim should be to control not only hypertension but also other correlated risk factors, such as obesity, glucose intolerance, insulin resistance, dyslipidemia, endothelial dysfunction and the prothrombotic state. Considering that remission from hypercortisolism is often difficult to achieve and that the cardiovascular risk can persist even during disease remission, care and control of all cardiovascular risk factors should be one of the primary goals during the follow-up of these patients.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20829618     DOI: 10.1159/000318566

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  25 in total

1.  Reversible cushing dilated cardiomyopathy mimicking peripartum cardiomyopathy with successful subsequent pregnancy.

Authors:  Rashed Al Banna; Aysha Husain; Jalila Al Aali; Khalid Ebrahim; Abdulaziz Mohammed
Journal:  BMJ Case Rep       Date:  2011-11-08

2.  A specific nursing educational program in patients with Cushing's syndrome.

Authors:  M Antonia Martínez-Momblán; Carmen Gómez; Alicia Santos; Nuria Porta; Julia Esteve; Inmaculada Úbeda; Irene Halperin; Beatriz Campillo; Montserrat Guillaumet; Susan M Webb; Eugenia Resmini
Journal:  Endocrine       Date:  2015-09-23       Impact factor: 3.633

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

Review 5.  Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management.

Authors:  Alicia Santos; Eugenia Resmini; Juan Carlos Pascual; Iris Crespo; Susan M Webb
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

6.  CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.

Authors:  G Koraćević; M Stojanović; S Petrović; D Simić; D Sakač; M Vlajković; M Stevic; M Kocić; M Đorđević; M Koraćević
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

7.  AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity?

Authors:  X Julia Xu; Rudy J Valentine; Neil B Ruderman
Journal:  Curr Obes Rep       Date:  2014-06-01

8.  Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.

Authors:  Jekaterina Patrova; Magnus Kjellman; Hans Wahrenberg; Henrik Falhammar
Journal:  Endocrine       Date:  2017-09-08       Impact factor: 3.633

Review 9.  Mifepristone: is there a place in the treatment of Cushing's disease?

Authors:  John D Carmichael; Maria Fleseriu
Journal:  Endocrine       Date:  2012-11-29       Impact factor: 3.633

Review 10.  Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess.

Authors:  Frederick Vogel; Martin Reincke
Journal:  Rev Endocr Metab Disord       Date:  2021-07-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.